ArticleJHEP reports : innovation in hepatology2026
Transcriptional and functional HBV-specific CD8 T cell changes from disease to functional cure in HBeAg-negative chronic hepatitis B.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research Progress on Mechanisms of Immune Tolerance Induced by Hepatitis B Surface Antigen in Chronic HBV Infection.Journal of immunology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: In chronic HBV infection, HBV-specific CD8 T cells are dysfunctional and comprise distinct subsets defined by phenotype and antigen specificity. We aimed to characterize the transcriptional and functional features of HBV-specific CD8 T-cell subsets in patients with HBeAg-negative chronic HBV infection who were either viremic (CHB) or had achieved spontaneous or nucleos(t)ide analogue (NUC)-induced HBsAg loss (RES), to better elucidate HBV-specific CD8 T-cell dysfunction and identify potential molecular targets for functional cure. Methods: Gene expression profiles of PD1 Results: Analysis of 84 genes concurrently expressed across all CD8 T-cell subsets identified an 11-gene signature describing a progressive transition from exhaustion-oriented PD1 Conclusions: Distinct exhaustion signatures characterize HBV-specific CD8 T-cell subsets and vary across disease phases. These findings support the development of individualized transcriptional and functional correction strategies and identify novel immune modulators with potential for immune-based anti-HBV therapies. Impact and implications: Exhausted HBV-specific CD8 T cells in chronic HBV infection are not a homogeneous population but comprise distinct subsets with differing capacities to control infection. This study identifies: (i) a transcriptional continuum of HBV-specific CD8 T-cell subsets spanning exhaustion to memory differentiation, reflecting disease progression and recovery in HBeAg-negative CHB; (ii) a core CD8 T-cell exhaustion gene signature characterized by progressively increased expression from memory-oriented to exhaustion-oriented subsets during active and resolution phases of disease; and (iii) the ability of targeted modulation of deregulated genes to restore antiviral CD8 T-cell function, with implications for the development of novel immune-based anti-HBV therapies. Overall, these findings advance our understanding of CD8 T-cell heterogeneity in chronic HBV infection and identify molecular targets for immunomodulatory strategies aimed at restoring CD8 T-cell functionality and achieving functional cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.